Patients with NF2 germline mutation have very different prognoses depending on ages of onset, tumor types, and types of genetic mutation; in a 30-year follow-up study of 353 patients, those observed to be symptomatic at age ≤25 had relatively poor prognoses, with about 10% dying 15 years after diagnosis, and the average life expectancy of those who died was in the 30s (Forde et al., 2021). This evidence concerns the gene NF2 and neoplasm.